We are live on ! Find out more
Krensavage Asset Management

Krensavage Asset Management Portfolio holdings

AUM $263M Turnover 10%
1-Year Est. Return 66.99%
This Fund
S&P 500
This Quarter Est. Return
+7.69%
1 Year Est. Return
+66.99%
3 Year Est. Return
+124.17%
5 Year Est. Return
+196.97%
10 Year Est. Return
+511.9%
AUM
$263M
AUM Growth
+$7.53M
Cap. Flow
-$3.25M
Cap. Flow %
-1.23%
Top 10 Hldgs %
89.38%
Holding
20
New
–
Increased
4
Reduced
2
Closed
2
Avg Time Held
2.4 years
Top 10 Avg Time Held
3.3 years
Top 20 Avg Time Held
2.4 years

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$17.8M
2
EMBC icon
Embecta
EMBC
+$2.18M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.36M
4
ARDX icon
Ardelyx
ARDX
+$211K

Top Sells

Rank Stock Value
1
INDV icon
Indivior Pharmaceuticals
INDV
+$10.3M
2
UTHR icon
United Therapeutics
UTHR
+$8.45M
3
ALKS icon
Alkermes
ALKS
+$3.81M
4
EXEL icon
Exelixis
EXEL
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ENTA icon
1
Enanta Pharmaceuticals
ENTA
$312M
$41.8M 15.88%
2,866,138
– –
2015 Q1
45 quarters
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$14B
$40.4M 15.36%
167,816
– –
2023 Q4
10 quarters
UTHR icon
3
United Therapeutics
UTHR
$25.7B
$37.5M 14.26%
69,282
-15,000
-18% -$8.45M
2014 Q4
46 quarters
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.3B
$30M 11.41%
524,786
– –
2025 Q3
3 quarters
EXEL icon
5
Exelixis
EXEL
$16.9B
$20.2M 7.66%
370,693
-45,000
-11% -$2.19M
2021 Q3
19 quarters
ABT icon
6
Abbott
ABT
$184B
$18.1M 6.89%
200,000
+195,000
+3,900% +$17.8M
2026 Q1
1 quarter
SNY icon
7
Sanofi
SNY
$106B
$13.8M 5.25%
323,946
– –
2023 Q4
10 quarters
SUPN icon
8
Supernus Pharmaceuticals
SUPN
$2.44B
$13.1M 4.96%
280,681
– –
2025 Q1
5 quarters
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$1.59B
$13.1M 4.96%
390,879
– –
2025 Q4
2 quarters
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$229M
$7.22M 2.74%
1,180,388
– –
2024 Q2
8 quarters
BNTX icon
11
BioNTech
BNTX
$22.1B
$5.54M 2.1%
59,523
– –
2024 Q1
9 quarters
GSK icon
12
GSK
GSK
$99.2B
$5.07M 1.93%
96,729
– –
2025 Q1
5 quarters
BIIB icon
13
Biogen
BIIB
$37.5B
$4.32M 1.64%
20,000
– –
2025 Q3
3 quarters
REGN icon
14
Regeneron Pharmaceuticals
REGN
$96B
$3.74M 1.42%
6,000
+2,000
+50% +$1.36M
2025 Q2
4 quarters
EMBC icon
15
Embecta
EMBC
$354M
$3.7M 1.41%
1,135,340
+400,000
+54% +$2.18M
2026 Q1
1 quarter
ARDX icon
16
Ardelyx
ARDX
$782M
$2.73M 1.04%
534,523
+34,523
+7% +$211K
2026 Q1
1 quarter
INMD icon
17
InMode
INMD
$761M
$1.77M 0.67%
120,942
– –
2026 Q1
1 quarter
EOLS icon
18
Evolus
EOLS
$485M
$1.1M 0.42%
157,985
– –
2025 Q3
3 quarters
ALKS icon
19
Alkermes
ALKS
$7.61B
– –
-107,822
Closed -$3.81M –
INDV icon
20
Indivior Pharmaceuticals
INDV
$4.17B
– –
-339,532
Closed -$10.3M –

Similar funds

VarCov Co
VarCov Co Darien, Connecticut $263M AUM
Alternative Investment Advisors
Alternative Investment Advisors Maitland, Florida $263M AUM 23.63% 1-Year Est. Return
BCM
Birmingham Capital Management Birmingham, Alabama $263M AUM 50.07% 1-Year Est. Return
GatePass Capital
GatePass Capital Independence, Ohio $263M AUM 39.37% 1-Year Est. Return
5th Street Advisors
5th Street Advisors Southport, Connecticut $263M AUM 20.47% 1-Year Est. Return
GGM Financials
GGM Financials Columbus, Ohio $264M AUM 15.28% 1-Year Est. Return
Navis Wealth Advisors
Navis Wealth Advisors Rye Brook, New York $264M AUM 35.41% 1-Year Est. Return
BWA
BlueChip Wealth Advisors Milton, Georgia $264M AUM 19.8% 1-Year Est. Return

Krensavage Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Krensavage Asset Management held 20 positions worth $263M, up 2.9% from $256M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Krensavage Asset Management's Q2 2026 filing shows 4 increased, 2 reduced and 2 closed positions. The largest sale was Indivior Pharmaceuticals, an estimated $10.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Krensavage Asset Management added most to Abbott in Q2 2026, an estimated $17.8M increase.
  • Krensavage Asset Management's biggest Q2 2026 reduction was United Therapeutics, cutting an estimated $8.45M.
  • Krensavage Asset Management fully exited Indivior Pharmaceuticals in Q2 2026, selling an estimated $10.3M.
  • Krensavage Asset Management's ten largest holdings make up 89% of its $263M portfolio in Q2 2026.
  • Krensavage Asset Management opened 0 new positions and closed 2 in Q2 2026.
  • Krensavage Asset Management's portfolio value rose 2.9% quarter-over-quarter to $263M.

Based on Krensavage Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.